Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 09-2025 | 09-2024 | 09-2023 | 09-2022 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -39,740 | -39,426 | -32,543 | -33,641 | -23,054 |
| Depreciation Amortization | 214 | 210 | 194 | 180 | 165 |
| Income taxes - deferred | 1,057 | 576 | 576 | 576 | N/A |
| Accounts payable and accrued liabilities | 8,767 | 2,000 | 1,762 | -112 | -579 |
| Other Working Capital | 1,053 | -1,685 | -4,006 | 240 | -2,717 |
| Other Operating Activity | 2,096 | 10,124 | 4,957 | 4,396 | 1,936 |
| Operating Cash Flow | $-26,553 | $-28,201 | $-29,060 | $-28,361 | $-24,250 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | N/A | -7 |
| Other Investing Activity | -5,750 | -5,000 | 0 | 0 | -40,000 |
| Investing Cash Flow | $-5,750 | $-5,000 | $N/A | $N/A | $-40,007 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,300 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 32,303 | 13,804 | 13,830 | N/A | 102,193 |
| Other Financing Activity | -300 | -3,831 | 0 | 0 | 18,278 |
| Financing Cash Flow | $33,303 | $9,972 | $13,830 | $N/A | $120,471 |
| Beginning Cash Position | 3,252 | 26,481 | 41,712 | 70,073 | 13,860 |
| End Cash Position | 4,252 | 3,252 | 26,481 | 41,712 | 70,073 |
| Net Cash Flow | $1,000 | $-23,229 | $-15,231 | $-28,361 | $56,213 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,553 | -28,201 | -29,060 | -28,361 | -24,250 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -7 |
| Free Cash Flow | -26,553 | -28,201 | -29,060 | -28,361 | -24,257 |